PERSISTENCE WITH BISPHOSPHONATE THERAPY AND RISK OF HIP FRACTURE

被引：0
|
作者：
Chodick, G. [1 ]
Shalev, V [1 ]
Sharon, Y. [2 ]
Goldstein, I [1 ]
机构：
[1] Maccabi Healthcare Serv, Tel Aviv, Israel
[2] Tel Aviv Univ, IL-69978 Tel Aviv, Israel
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 03期
关键词：
D O I：
10.1016/j.jval.2011.02.691
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A124 / A124
页数：1
相关论文
共 50 条
  • [1] EXTENDED BISPHOSPHONATE THERAPY NOT ASSOCIATED WITH REDUCED HIP FRACTURE RISK
    Rosenberg, Karen
    AMERICAN JOURNAL OF NURSING, 2021, 121 (04) : 47 - 47
  • [2] The association between compliance and persistence with bisphosphonate therapy and fracture risk: A review
    Adachi, Jonathan
    Lynch, Niall
    Middelhoven, Hans
    Hunjan, Manjit
    Cowell, Warren
    BMC MUSCULOSKELETAL DISORDERS, 2007, 8 (1)
  • [3] The association between compliance and persistence with bisphosphonate therapy and fracture risk: A review
    Jonathan Adachi
    Niall Lynch
    Hans Middelhoven
    Manjit Hunjan
    Warren Cowell
    BMC Musculoskeletal Disorders, 8
  • [4] Persistence with bisphosphonate therapy and fracture risk in postmenopausal women in a managed care environment.
    Gold, D
    Cosman, F
    Frytak, J
    Baran, R
    Amonkar, M
    Martin, B
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S399 - S399
  • [5] The impact of sub optimal compliance and persistence with bisphosphonate therapy on post menopausal osteoporotic fracture risk
    Cowell, W.
    Lynch, N. O.
    Middelhoven, H.
    Hunjan, M.
    CALCIFIED TISSUE INTERNATIONAL, 2007, 80 : S120 - S120
  • [6] Persistence with bisphosphonate treatment and fracture risk in a managed care setting
    Cosman, F
    Gold, DT
    Frytak, J
    Baran, RW
    Amonkar, MM
    Martin, B
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2005, 12 (06): : 795 - 795
  • [7] Impact of persistence with bisphosphonate therapy on fracture risk and costs among postmenopausal women in a managed care environment
    Gold, DT
    Cosman, F
    Frytak, J
    Baran, RW
    Amonkar, M
    Martin, B
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S292 - S292
  • [8] Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan
    Y.-K. Soong
    K.-S. Tsai
    H.-Y. Huang
    R.-S. Yang
    J.-F. Chen
    P. C.-H. Wu
    K.-E. Huang
    Osteoporosis International, 2013, 24 : 511 - 521
  • [9] THE RISK OF REFRACTURE ASSOCIATED WITH THE COMPLIANCE AND THE PERSISTENCE WITH BISPHOSPHONATE THERAPY IN TAIWAN
    Soong, Y.
    Tsai, K.
    Chen, J.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 : 279 - 279
  • [10] THE RISK OF REFRACTURE ASSOCIATED WITH THE COMPLIANCE AND THE PERSISTENCE WITH BISPHOSPHONATE THERAPY IN TAIWAN
    Su, Y. J.
    Lin, M. J.
    Tsai, I. C.
    Soong, Y. K.
    VALUE IN HEALTH, 2010, 13 (07) : A557 - A558
12345